

Head and Neck Disease-Oriented Team

Clinical Research Treatment Trial Flowchart

Clinical Research Manager:

Mehir Tharani

Clinical Research Coordinators:

Bao-An Huynh

Natalie Arechiga

Erin Palmer-Torrison

Anastasiia Reipolska



Open to Accrual
 Low Accruing
 Pending Activation/Suspended

Definitive HNSCC

UCI 22-132
 De-escalated Radiation HPV 16+ SCC OPC
 Coord: E. Palmer-Torrison
 Accrual: 17/111

UCI 21-173
 AHCC w/ SOC Tx
 HPV+ HNSCC
 Coord: A. Reipolska
 Mushroom Extract
 Accrual: 3/34

HN009
 Cisplatin Q3 weeks vs Weekly
 Locally Advanced HNSCC
 Coord: A. Reipolska
 Accrual: 1/5

Adjuvant

EA3132 (TP53)
 XRT +/- Cisplatin
 Adjuvant
 Coord: A. Reipolska
 Accrual: 0/5

UCI 23-190
 Observation vs IP
 Adjuvant
 Coord: E. Palmer-Torrison
 Accrual: 0/5

Re-radiation

EA3191
 Pembrolizumab
 Adjuvant Recurrent/2ndary HNSCC
 Coord: N. Arechiga
 Accrual: 0/5



1st Line Recurrent/Metastatic HNSCC

UCI 24-130
HPV injection + Pembro
1st line Recurrent/Metastatic
Coord: TBD
Accrual: TBD
opens August 2025

RTOG 3521
Gem+Cis+ Tori
1st line Recurrent/Metastatic NPC
Coord: N. Arechiga
Accrual: 1/5

Recurrent/Metastatic

UCI 25-49
Petosemtamab vs Phys Choice
Recurrent HNSCC
CRC: TBD
Accrual: TBD

Alliance A092105
2nd line Ipi/Nivo +/- Cabozantinib
Recurrent NPC
Coord: B. Huynh
Accrual: 0/5

ETCTN 10553
Darolutamide + Leuprolide Acetate in
Hormone Naïve AR+ Salivary Gland Cancer
Coord: B. Huynh
Accrual: 2/5

EA3231
BRAF Agent vs Cabozantinib
Recurrent Thyroid Cancer
Coord: E. Palmer-Torrison
Accrual: 0/5



Broad Phase 1 Trials

UCI 22-87
(RMC-6236)

Mechanism: TKI
Coordinator: Oliver
Quines
Accrual: 21/25

UCI 21-40

*(Locally Advanced or Metastatic
Solid Tumors)*

DF6002 as a Monotherapy
and in Combination w/ nivo
Valerin
CRC: B. Huynh
Accrual: 5/10
Waitlist only

UCI 25-106

IP Monotherapy
HNSCC, 2L+ sq/nsq NSCLC, TNBC
Coord: TBD
Accrual: TBD

UCI 23-148

CJRB-01 (oral) +
Pembrolizumab
Mechanism: Live
biotherapeutic product
containing a novel strain
belonging in the species
Leuconostoc
mesenteroides (*L.*
mesenteroides +
Pembrolizumab
Coord: J. Choe
Accrual: 3/6
accrual hold~ July 2025

UCI 23-197

DF6215 (IL-2)
PI: Valerin
CRC: N. Arechiga
Accrual: 5/10
Waitlist only

UCI 22-09

B7-H4-targeted antibody-drug
conjugate
PI: Parajuli
CRC: N. Arechiga
Accrual: 6/10
Waitlist only